AMRUTANJAN HEALTH CARE
BSE ticker code |
590006 |
NSE ticker code |
AMRUTANJAN |
Major activity |
Pharmaceuticals |
Managing Director |
Sambhu Prasad Sivalenka |
Equity capital |
Rs. 2.92 crore; FV Re. 01 |
52 week high/low |
Rs. 1026 / Rs. 472 |
CMP |
Rs. 832.85 |
Market Capitalisation |
Rs. 2523.54 crore |
Recommendation |
Accumulate at declines |
Going beyond its legendary balm
mrutanajan Health Care is an Indian pharmaceutical company engaged in the manufacture of
ayurvedic
health care products and beauty products. The company has
diversified into information technology and the food business.
Amrutanjan Infotech is engaged in IT services and business
process outsourcing. Through acquisition of Siva’s Soft Drink
Pvt Ltd, a Chennai-based company, it also started manufacturing fruit juices under the
brand
name ‘Fruitnick’. The company is internationally known for its Amrutanjan
balm. It is growing slowly but steadily
on the financial front and its prospects
ahead are quite healthy for investors.
Consider:
-
The company, mainly
known for its balm – a headache pain
remover – for the last 100 years is a
household name for this product.
-
The company is growing but
very slowly. During the last five years
its sales turnover has steadily increased from Rs. 219.63 crore
in the fiscal 2017 to Rs. 332.84 crore in the fiscal 2021 with
the operating profit moving up from Rs. 29.44 crore to Rs.
74.75 crore and the profit at net level inching up from Rs.
22.35 crore to Rs. 61.19 crore respectively during this five
year period. The company's balance sheet is very healthy with
strong financial position, its reserves at the end of March 31,
2021 standing at Rs. 212.64 crore - over 71 times its tiny
equity capital of Rs. 2.92 crore. This is virtually a debt-free
company with its interest during the fiscal 2021 being a fractional Rs. 50 lakh
with rising demand for Ayurvedic medicines, the company's margins are on the
rise.
-
With a view to achieving 113 per cent of its national sales through the
e-commerce route, Amrutanjan has
started investing in digitzation in a big way, building on the
sales force automation project that was rolled out earlier by
building a dashboard that seamlessly integrates data flow from
various sources. Part of the digitization is also to offer its products for sale
on its corporate website. Today, its products are
available online on Amazon, Pharmeasy, Netmeds and Apollo.
At present, the company has recorded sales of around Rs 1.92
crore through this route and the management wants to raise
it to around Rs 5 crore in the first instance. Initially, the company would like
to focus on growing the pain balm, health
beverages and woman’s hygiene portfolio through this e-commerce route. The
company is also working on a mobile application on its popular Comfi brand of
sanitary napkins and related products,
aimed at serving women in tracking
menstrual and feminine health.
-
Amrutanjan has
planned an aggressive marketing strategy. Accordingly, now it focuses on
building distribution for its brands with
the ‘M5K’ plan that targets a vision of
appointing 5,000 distributors and subdistributors. Over a year ago, the company
had appointed around 1,000 distributors and sub-distributors, improving direct
coverage from 3,950 to 4,500 towns. Now, it would
like to grow its distribution of its products to regions in the western and
northern zones where its business is relatively weak.
-
In the meanwhile, the company has extended its product range instead of
depending only on its pain balm. It launched
an innovative back pain ‘Rollon’ format which became a runaway success. What is
more. its competitors were forced to
copy it. Again, Amrutanjan was the first company to introduce
a Rs 2 sachet which was later copied by Zandu, its major competitor. The company
also increased the efficacy of its products by augmenting the menthol content
and launched a new
cardboard packaging. All these changes have injected new life
into the 125-year-old company.
-
The company has also entered the female hygiene
category through its Comfy brand of sanitary pads, which is
positioned as an affordable brand and targets users from semiurban and rural
India. This is considered a category worth Rs
1,800-2,000 crore and major players Stayfree and Whisper
enjoy a big share of this market. Amrutanjan has tremendous
scope for promoting its product in the semiurban and village segments of th
Shares of the company are quoted
around Rs 825. We feel this is quite an
attractive bet. Investors with a long perspective will be able to reap rich harvest
by investing in this company.
PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Sales
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2018-19
|
253.20
|
24.50
|
8.40
|
215.0
|
51.10
|
17.90
|
2019-20
|
261.50
|
154.40
|
8.60
|
210.0
|
54.50
|
16.40
|
2020-21
|
332.84
|
61.12
|
20.90
|
420.0
|
81.80
|
32.60
|
ADVANCED ENZYME TECHNOLOGIES
BSE ticker code |
540025 |
NSE ticker code |
ADVENZYMES |
Major activity |
Agricultural Products |
Chairman |
Vasant Rathi |
Equity capital |
Rs. 22.36 crore; FV Rs. 02 |
52 week high/low |
Rs. 503 / Rs. 297 |
CMP |
Rs. 348.00 |
Market Capitalisation |
Rs. 3890.34 crore |
Recommendation |
Buy at declines |
Growing global enzyme footprint
Advanced Enzyme Technologies may be a small
cap but it’s the largest enzyme manufacturing company in India. During the last two
decades, it has transformed itself into
a global enzyme powerhouse based on its R&D and tech innovation. It manufactures
400-plus proprietary products developed from over 68 indigenous enzymes and products.
The company
is one of the few manufacturers in
the world to possess great depth and
expertise in fermented manufacturing. AET has excellent growth prospects going ahead.
Consider:
-
The company caters to diversified industries and verticals like
human nutrition, animal nutrition and
bio-processing. It provides its proprietary enzyme products and customized
enzyme products to various pharmaceutical and nutraceutical
companies in India, other Asian countries, North America and
Europe. The company has state-of-the-art manufacturing facilities and R&D
centres across India, the US and Germany
-
AET has expanded its operations through the acquisition route. It acquired
several companies, including CalIndia Foods International (which gave AET a
direct presence
in the US), Advanced Supplementary Technologies Corporation (which consolidated
its presence in the US), JC Biotech
Pvt Ltd, AEM of Malaysia and Evoxx Technologies GmbH.
Today, the company has three wholly owned subsidiaries, three
joint ventures and five step-down subsidiaries, all of which
help AET service 700 clients spread across 45 countries.
-
With these acquisitions, the company has made slow
but steady progress on the financial front. During the last 11
years, its sales turnover has advanced from Rs 116 crore in
fiscal 2011 to Rs 502 crore in fiscal 2021, with the operating
profit growing from Rs 23 crore to Rs 232 crore and the net
profit inching up from Rs 17 crore to Rs 146 crore during this
period. The company’s financial position is very strong, with
reserves at the end of March 2021 standing at Rs 948 crore –
more than 43 times its equity capital of Rs 22 crore. As its debt
is negligible (Rs 23 crore), it is virtually a debt-free company.
GLOBAL POTENTIAL
From 2022 to 2028, the global
technical enzymes market is expected to develop at a fast pace, according to the
latest MarketsandResearch.biz document.
For the forecast period, the paper
proposes a marketshare estimation
in terms of volumes. This study
looks at the market definition, classifications, applications, engagements and global
technical enzymes
enterprise trends.
The local evaluation phase reveals the substantial capability of every region in the
global technical enzymes marketplace collectively with its period and amount. The study
explains expansion techniques and procedures, estimates,
production processes and fee structures. It also consists of
product offerings, revenue evaluation, production capabilities, gross margins and
numerous different crucial elements
that effect the profitability of the company involved in the
market. Advanced Enzymes Technologies will be one of the
major beneficiaries of this market potential.
-
Prospects ahead are highly promising as enzymes
are used in a wide variety of industries like human healthcare
and nutrition, animal nutrition, banking, fruit and vegetable
processing, brewing and malting, grain processing, protein
modification, dairy processing, speciality applications and
textile processing. The management expects sales to cross the
Rs 1,000-crore mark within the next five years, with a corresponding improvement
in earnings.
-
The company’s shareholding is in strong hands, with
the promoters holding 52.55
per cent, foreign institutional
investors (FIIs) 16.27 per
cent and domestic institutional investors (DIIs) 8.67
per cent.
CONSOLIDATED PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Sales
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2018-19
|
419.60
|
111.20
|
10.00
|
30.0
|
66.60
|
18.00
|
2019-20
|
444.00
|
129.30
|
11.60
|
30.0
|
75.20
|
17.00
|
2020-21
|
501.84
|
145.69
|
13.00
|
45.0
|
91.70
|
16.10
|
ADC INDIA COMMUNICATIONS
BSE ticker code |
522074 |
NSE ticker code |
ELGIEQUIP |
Major activity |
Industrial Machinery |
Managing Director |
Jairam Varadaraj |
Equity capital |
Rs. 31.69 crore; FV Re. 01 |
52 week high/low |
Rs. 423 / Rs. 173 |
CMP |
Rs. 306.50 |
Market Capitalisation |
Rs. 9713.26 crore |
Recommendation |
Buy at declines |
Financials poor, potential high
Headquartered in Bengaluru, ADC India
Communications (formerly known as Krone Communications)
is a leading player in broadband connectivity and provides
connection solutions for wireline, wireless, cable broadcast
and enterprise networks. The company is an undisputed leader
in providing network infrastructure
products and services that support
its customers in migration to next
generation networks. It plays a crucial role in enabling customers to
deliver dynamic video, data, voice
and wireless services that are increasingly essential to telcos, enterprises and
infrastructure providers.
Despite its important role, ADC’s
shares are quoted at below intrinsic
value and hence are worth buying.
Consider:
-
The telecom sector continues to be at the epicentre
for growth, innovation and disruption for virtually any industry. According to a
study, smartphones today account for two
out of every three mobile connections globally. Mobile devices and related
broadband connectivity continue to be more
and more embedded in our daily life and are key in driving
the momentum around key trends like video streaming, Internet
of Things (IoT) and mobile payments. This trend is a key
growth driver for ADC India Communications.
-
The company expects higher growth in the medium
term driven by demand from infrastructure projects, the defence sector,
e-commerce, hospitality, education, IT/ITeS and
government projects. The company expects growth in the fiber business vis-à-vis
copper due to the large infrastructure
corridors, the national fiber optic network, and the ‘Digital
India’ and ‘Smart City’ initiatives.
-
ADC has introduced new products like a fiber and
copper patch lock system, which helps customers look at an
additional level of physical security in critical connectivity requirements, and
also continues its work in supporting highdensity fiber requirements for
co-locations with better manageability feature
-
Communications service providers across the globe
are continuing their rapid migration to next-generation networks that can
deliver reliable
broadband services over any device
anytime, anywhere. At the same
time, high speed enterprise networks
and data centres continue to be built
to meet the challenge of transmitting
and storing the vast amounts of information critical for success in modern
business. The need for ubiquitous access, scalable bandwidth and
robust, reliable connectivity is no different for a carrier, cable company
or enterprise. All depend on ADC's
network infrastructure expertise to help them design and deploy high-speed wired
networks offering dynamic video, data,
and voice to businesses and consumers.
-
The company has also introduced new products
that would cater to the telecom market such as fiber-to-antenna and
copper-to-antenna products that will help support upcoming 4G projects. It has
also introduced outdoor
environment enclosures/cable assembly products to support
the security and surveillance market and continues its focus
on a standard-compliant product portfolio to increase its geographical reach
-
The company’s financial performance so far is not
that heart-warming. During the last five years, its sales have
declined marginally from Rs 62.32 crore in fiscal 2017 to Rs
126.60 crore in fiscal 2021, with the operating profit inching
up fractionally from Rs 3.63 crore to Rs 4.84 crore and the
net profit declining from Rs 3.82 crore to Rs 3.62 crore during
this period. A plus point for the company is that it is a debtfree entity and is
regular in payment of dividends, the rate for
the last year being 25 per cent.
According to research analysts, at the
current price of Rs. 380, the scrip is undervalued on the basis of its intrinsic value,
which is Rs 522 as determined by the median of 3 historical modes.
PERFORMANCE INDICATORS (Rs. in crore)
Year
|
Net Series
|
Net Profit
|
EPS (Rs.)
|
Div (%)
|
BV (%)
|
RONW (%)
|
2018-19
|
85.62
|
5.86
|
12.70
|
----
|
110.00
|
7.82
|
2019-20
|
78.13
|
3.80
|
8.30
|
20.0
|
87.30
|
9.63
|
2020-21
|
59.86
|
3.61
|
7.80
|
25.0
|
98.80
|
8.69
|